Patents by Inventor Masatoshi Yuri
Masatoshi Yuri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897954Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.Type: GrantFiled: November 15, 2021Date of Patent: February 13, 2024Assignees: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki Tenda, Masatoshi Yuri, Daisuke Yamajuku, Takeshi Tsutsumi, Yuko Kusuzaki, Hiroki Sasaki, Fumiko Chiwaki, Masayuki Komatsu
-
Publication number: 20230348587Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.Type: ApplicationFiled: November 15, 2021Publication date: November 2, 2023Applicants: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki TENDA, Masatoshi YURI, Daisuke YAMAJUKU, Takeshi TSUTSUMI, Yuko KUSUZAKI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
-
Publication number: 20080213800Abstract: It has been found that the urine from an IC patient shows a high value in amount and the existence of activity of an azurophilic granular substance, thereby to establish a method for examining IC. The present invention relates to a method for examining interstitial cystitis using the kinetics of an azurophilic granular substance in urine as a marker. Also, the present invention relates to a kit for examining interstitial cystitis for use in the examination method, a use of an azurophilic granular substance as a test marker for examining interstitial cystitis or evaluating pharmacological effects of a drug, and a method for examining therapeutic effects on a patient with interstitial cystitis using an azurophilic granular substance as a marker.Type: ApplicationFiled: May 19, 2005Publication date: September 4, 2008Applicant: ASTELLAS PHARMA INC.Inventors: Tetsuo Yamada, Haruhisa Mita, Sadao Kuromitsu, Hiroyuki Yokota, Shuji Morita, Masashi Hiramoto, Masatoshi Yuri
-
Patent number: 7329665Abstract: An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents —CH? or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.Type: GrantFiled: August 2, 2002Date of Patent: February 12, 2008Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Masami Muraoka, Kazuki Matsui, Takaaki Yamamoto, Koji Morishita, Masatoshi Yuri, Seiji Katayama, Naohito Ohashi
-
Publication number: 20050032819Abstract: An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents —CH? or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.Type: ApplicationFiled: August 2, 2002Publication date: February 10, 2005Inventors: Masami Muraoka, Kazuki Matsui, Takaaki Yamamoto, Koji Morishita, Masatoshi Yuri, Seiji Katayama, Naohito Ohashi
-
Patent number: 6734205Abstract: A compound represented by the following formula: wherein R is a substituted or unsubstituted benzene ring, a fused polycyclic hydrocarbon ring which is substituted or unsubstituted, a monocyclic heterocyclic ring which is substituted or unsubstituted, a polycyclic heterocyclic ring which is substituted or unsubstituted, A and E are independently a single bond, a lower alkylene group or the like, G is a single bond, an oxygen atom or the like, and Y is a —SO3H group or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton exchange transport system.Type: GrantFiled: June 17, 2002Date of Patent: May 11, 2004Assignee: Sumitomo Pharmaceuticals Company LimitedInventors: Masahumi Kitano, Masatoshi Yuri, Naohito Ohashi
-
Publication number: 20030018056Abstract: A compound represented by the following formula: 1Type: ApplicationFiled: June 17, 2002Publication date: January 23, 2003Inventors: Masahumi Kitano, Masatoshi Yuri, Naohito Ohashi
-
Patent number: 6452008Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alkyl, etc.Type: GrantFiled: May 14, 2001Date of Patent: September 17, 2002Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
-
Publication number: 20010051732Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety.Type: ApplicationFiled: May 14, 2001Publication date: December 13, 2001Applicant: SUMITOMO PHARMACEUTICALS COMPANY, LIMITEDInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
-
Patent number: 6300500Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alky, etc.Type: GrantFiled: August 25, 2000Date of Patent: October 9, 2001Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi